Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 PCSK9 as a therapeutic target in atherosclerosis.

Literature DB >> 20425252

PCSK9 as a therapeutic target in atherosclerosis.

Ali J Marian¹.

Abstract

Entities: Disease Gene

Year: 2010 PMID： 20425252 DOI： 10.1007/s11883-010-0099-2

Source DB: PubMed Journal: Curr Atheroscler Rep ISSN： 1523-3804 Impact factor: 5.113

× No keyword cloud information.

12 in total

1. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

Authors: Jonathan C Cohen; Eric Boerwinkle; Thomas H Mosley; Helen H Hobbs
Journal: N Engl J Med Date: 2006-03-23 Impact factor: 91.245

2. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.

Authors: Jonathan Cohen; Alexander Pertsemlidis; Ingrid K Kotowski; Randall Graham; Christine Kim Garcia; Helen H Hobbs
Journal: Nat Genet Date: 2005-01-16 Impact factor: 38.330

3. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice.

Authors: Mark J Graham; Kristina M Lemonidis; Charles P Whipple; Amuthakannan Subramaniam; Brett P Monia; Stanley T Crooke; Rosanne M Crooke
Journal: J Lipid Res Date: 2007-01-22 Impact factor: 5.922

4. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote.

Authors: Zhenze Zhao; Yetsa Tuakli-Wosornu; Thomas A Lagace; Lisa Kinch; Nicholas V Grishin; Jay D Horton; Jonathan C Cohen; Helen H Hobbs
Journal: Am J Hum Genet Date: 2006-07-18 Impact factor: 11.025

5. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis.

Authors: Suet N Chen; Christie M Ballantyne; Antonio M Gotto; Yanli Tan; James T Willerson; Ali J Marian
Journal: J Am Coll Cardiol Date: 2005-04-21 Impact factor: 24.094

6. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice.

Authors: Thomas A Lagace; David E Curtis; Rita Garuti; Markey C McNutt; Sahng Wook Park; Heidi B Prather; Norma N Anderson; Y K Ho; Robert E Hammer; Jay D Horton
Journal: J Clin Invest Date: 2006-11 Impact factor: 14.808

7. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

Authors: Marianne Abifadel; Mathilde Varret; Jean-Pierre Rabès; Delphine Allard; Khadija Ouguerram; Martine Devillers; Corinne Cruaud; Suzanne Benjannet; Louise Wickham; Danièle Erlich; Aurélie Derré; Ludovic Villéger; Michel Farnier; Isabel Beucler; Eric Bruckert; Jean Chambaz; Bernard Chanu; Jean-Michel Lecerf; Gerald Luc; Philippe Moulin; Jean Weissenbach; Annick Prat; Michel Krempf; Claudine Junien; Nabil G Seidah; Catherine Boileau
Journal: Nat Genet Date: 2003-06 Impact factor: 38.330

8. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.

Authors: Paul M Ridker; Eleanor Danielson; Francisco Ah Fonseca; Jacques Genest; Antonio M Gotto; John Jp Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G Macfadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Robert J Glynn
Journal: Lancet Date: 2009-03-28 Impact factor: 79.321

3. Accelerated atherosclerosis development in C57Bl6 mice by overexpressing AAV-mediated PCSK9 and partial carotid ligation.

Authors: Sandeep Kumar; Dong-Won Kang; Amir Rezvan; Hanjoong Jo
Journal: Lab Invest Date: 2017-05-15 Impact factor: 5.662

3 in total